<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39354682</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2049-632X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Pathogens and disease</Title><ISOAbbreviation>Pathog Dis</ISOAbbreviation></Journal><ArticleTitle>Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in acute phase of COVID-19, convalescents and pre-pandemic individuals.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ftae025</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/femspd/ftae025</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have already infected more than 0.7 billion people and caused over 7 million deaths worldwide. At the same time, our knowledge about this virus is still incipient. In some cases, there is a pre-pandemic immunity, however its source is unknown. The analysis of patients' humoral responses might shed a light on this puzzle. In this paper, we evaluated the antibody recognition of nucleocapsid protein, one of the structural proteins of SARS-CoV-2. For this purpose, we used pre-pandemic, acute COVID-19 and convalescent patients' sera to identify and map nucleocapsid protein epitopes. We identified a common epitope KKSAAEASKKPRQKRTATKA recognized by sera antibodies from all three groups. Some motifs of this sequence are widespread among various coronaviruses, plant or human proteins indicating that there might be more sources of nucleocapsid-reactive antibodies than previous infection with seasonal coronavirus. The two sequences MSDNGPQNQRNAPRITFGGP and KADETQALPQRQKKQQTVTL were detected as specific for sera from patients in acute phase of infection and convalescents making them suitable for future development of vaccine against SARS-CoV-2. Knowledge of the humoral response to SARS-CoV-2 infection is essential for the design of appropriate diagnostic tools and vaccine antigens.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of FEMS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Razim</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5471-7013</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacyga-Prus</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazana-Płuszka</LastName><ForeName>Wioletta</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zabłocka</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macała</LastName><ForeName>Józefa</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciepłucha</LastName><ForeName>Hubert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wybrzeże L. Pasteura 1, 50-367 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamian</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Górska</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pathog Dis</MedlineTA><NlmUniqueID>101595366</NlmUniqueID><ISSNLinking>2049-632X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">binding antibody</Keyword><Keyword MajorTopicYN="N">coronaviruses</Keyword><Keyword MajorTopicYN="N">epitope mapping</Keyword><Keyword MajorTopicYN="N">humoral immunity</Keyword><Keyword MajorTopicYN="N">nucleocapsid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354682</ArticleId><ArticleId IdType="doi">10.1093/femspd/ftae025</ArticleId><ArticleId IdType="pii">7804360</ArticleId></ArticleIdList></PubmedData></PubmedArticle>